Research graph
References from Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study. Local targets link to admitted publications; unresolved targets remain external evidence.
10.2337/diacare.15.3.318
10.2337/diacare.15.3.318 · External reference
10.1016/s1056-8727(96)00050-5
10.1016/s1056-8727(96)00050-5 · External reference
10.2337/diacare.16.2.434
10.2337/diacare.16.2.434 · External reference
10.1016/s0002-8703(98)70072-9
10.1016/s0002-8703(98)70072-9 · External reference
10.7326/0003-4819-121-12-199412150-00002
10.7326/0003-4819-121-12-199412150-00002 · External reference
10.1001/archopht.116.3.297
10.1001/archopht.116.3.297 · External reference
10.1016/s0140-6736(98)07019-6
10.1016/s0140-6736(98)07019-6 · External reference
10.1016/s0140-6736(98)07037-8
10.1016/s0140-6736(98)07037-8 · External reference
Tight glycaemic control prevents diabetic complications.
10.1080/17843286.1995.11718471 · 1995 · External reference
10.1021/jm00049a017
10.1021/jm00049a017 · External reference
Identification of high‐affinity binding sites for the insulin sensitizer rosiglitazone (BRL‐49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator‐activated receptor gamma.
10.1016/s0022-3565(24)37268-4 · 1998 · External reference
10.1055/s-2007-979932
10.1055/s-2007-979932 · External reference
Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNAs in pancreatic islets.
1998 · External reference
10.2337/diabetes.43.10.1203
10.2337/diabetes.43.10.1203 · External reference
The glitazone family of antidiabetic agents.
10.2174/1381612802666220920215821 · 1996 · External reference
10.1074/jbc.270.22.12953
10.1074/jbc.270.22.12953 · External reference
10.1111/j.1749-6632.1996.tb18621.x
10.1111/j.1749-6632.1996.tb18621.x · External reference
10.1172/jci119870
10.1172/jci119870 · External reference
10.2337/diab.28.12.1039
10.2337/diab.28.12.1039 · External reference
Estimation of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge.
10.1093/clinchem/18.6.499 · 1972 · External reference
10.7326/0003-4819-128-3-199802010-00002
10.7326/0003-4819-128-3-199802010-00002 · External reference
Cardiac and glycaemic benefits of troglitazone treatment in NIDDM.
10.2337/diab.46.3.433 · 1997 · External reference
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients.
10.1007/bf00418542 · 1996 · External reference
Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
10.2337/diab.45.12.1661 · 1996 · External reference
10.1002/(sici)1096-9136(199805)15:5<360::aid-dia568>3.0.co;2-w
10.1002/(sici)1096-9136(199805)15:5<360::aid-dia568>3.0.co;2-w · External reference
